Skip to main content
VVVV
NYSE Life Sciences

vVardis Falls 22% in NYSE Debut After $175M IPO Priced Below Range

Tom Rudovsky · Reported by Reuters
More coverage: Healthcare
Sentiment info
Negative
Importance info
7
Price
$14.92
Mkt Cap
--
52W Low
$14
52W High
$15.27
52W Position info
6.6% above low
Off High info
2.3% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

VVVV is trading near its 52-week low of $14 (6.6% above the low).

Summary

vVardis raised $175 million in its NYSE IPO but priced below the marketed range, and the stock fell 22% on its first day of trading. The weak debut follows this morning's pricing announcement and tells you demand was soft even at the reduced level. For a dental med-tech name selling the Curodont non-invasive cavity treatment brand, a broken IPO print is a rough start to public-market life. Apollo (APO) is tagged alongside but is not the subject of this story.

At the time of this announcement, VVVV was trading at $14.92 on NYSE in the Life Sciences sector. The 52-week trading range was $14.00 to $15.27. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

VVVV - Latest Insights

VVVV
Nov 13, 2026, 12:02 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: N/A
Real-time Price: $16.10 info
Change: N/A info
Market Cap: N/A info